<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li T</submitter><funding>Natural Science Foundation of Zhejiang Province</funding><pagination>295</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10064697</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The prognostic value of cytokeratin 19 fragment (CYFRA 21 - 1) and Ki67 in advanced non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) remains to be explored.&lt;h4>Methods&lt;/h4>In this study, 983 primary NSCLC patients from January 2016 to December 2019 were retrospectively reviewed. Finally, 117 advanced NSCLC patients with wild-type EGFR and 37 patients with EGFR mutation were included and prognostic value of CYFRA 21 - 1 and Ki67 were also identified.&lt;h4>Results&lt;/h4>The patients age, smoking history and the Eastern Corporative Oncology Group (ECOG) performance scores were significantly different between CYFRA21-1 positive and negative groups (p &lt; 0.05), while no significant differences were found in Ki67 high and low groups</pubmed_abstract><journal>BMC cancer</journal><pubmed_title>Prognostic value of CYFRA 21 - 1 and Ki67 in advanced NSCLC patients with wild-type EGFR.</pubmed_title><pmcid>PMC10064697</pmcid><funding_grant_id>LY18H200006</funding_grant_id><pubmed_authors>Zheng XQ</pubmed_authors><pubmed_authors>Wang XM</pubmed_authors><pubmed_authors>Li T</pubmed_authors><pubmed_authors>Luo Z</pubmed_authors><pubmed_authors>Yan GL</pubmed_authors><pubmed_authors>Fang YY</pubmed_authors><pubmed_authors>Xie Q</pubmed_authors><pubmed_authors>Sun Y</pubmed_authors><pubmed_authors>He JB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prognostic value of CYFRA 21 - 1 and Ki67 in advanced NSCLC patients with wild-type EGFR.</name><description>&lt;h4>Background&lt;/h4>The prognostic value of cytokeratin 19 fragment (CYFRA 21 - 1) and Ki67 in advanced non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) remains to be explored.&lt;h4>Methods&lt;/h4>In this study, 983 primary NSCLC patients from January 2016 to December 2019 were retrospectively reviewed. Finally, 117 advanced NSCLC patients with wild-type EGFR and 37 patients with EGFR mutation were included and prognostic value of CYFRA 21 - 1 and Ki67 were also identified.&lt;h4>Results&lt;/h4>The patients age, smoking history and the Eastern Corporative Oncology Group (ECOG) performance scores were significantly different between CYFRA21-1 positive and negative groups (p &lt; 0.05), while no significant differences were found in Ki67 high and low groups</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2025-05-29T19:45:53.434Z</modification><creation>2025-04-04T21:10:09.508Z</creation></dates><accession>S-EPMC10064697</accession><cross_references><pubmed>37004004</pubmed><doi>10.1186/s12885-023-10767-9</doi></cross_references></HashMap>